The Week in Review: Quintiles to Build China Headquarters in Shanghai
07:55 EDT 24 Jun 2012 | ChinaBio Today
Quintiles will invest $14 million to build a regional headquarters for China in Shanghai’s Feng Lin Science Park; Ascepion Pharma of Suzhou out-licensed worldwide rights for an oncology drug candidate to Debiopharm Group™ of Switzerlan..
Original Article: The Week in Review: Quintiles to Build China Headquarters in Shanghai
More From BioPortfolio on "The Week in Review: Quintiles to Build China Headquarters in Shanghai"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
